Followers | 218 |
Posts | 38765 |
Boards Moderated | 0 |
Alias Born | 04/29/2008 |
Friday, June 09, 2017 9:42:49 PM
Aside from the billions of diluting shares from toxic loans, Mersky has complete voting control through preferred shares and a complete lock on any company value through 2 additional preferred share classes.
Common shareholders are holding worthless shares IMHO. And getting more worthless with each toxic conversion.
https://www.otcmarkets.com/financialReportViewer?symbol=DRNK&id=172719
Series A Preferred Stock
The Board of Directors have designated 10,000,000 shares as Series A Preferred Stock. The Designation of the Series A Preferred Stock, as amended, includes voting rights whereas, for so long as any shares of the Series A Preferred Stock remain issued and outstanding, the holders thereof, voting separately as a class, shall have the right to vote on all shareholder matters with a vote equal to fifty-one percent (51%) of all the issued and outstanding capital stock of the Corporation on a fully diluted basis of the total vote on matters to which all shareholders of the Corporation are entitled to vote. The Series A Preferred Stock does not have any conversion rights or liquidation rights. As of March 31, 2017 and December 31, 2016, there are 10,000,000 shares of Series A Preferred Stock issued and outstanding, owned by David Mersky, the Company’s CEO.
Series B Preferred Stock
The Board of Directors of the Company have designated 25,000,000 shares as Series B Preferred Stock. The Designation of the Series B Preferred Stock, as amended, includes conversion rights, whereby the holders of Series B Preferred Stock shall have shall have the right to convert each share of Series B Preferred Stock into one hundred forty (140) shares of common stock of the Company. The Series B Preferred Stock has no voting rights or liquidation rights. As of March 31, 2017 and December 31, 2016, there are 21,600,000 shares of Series B Preferred Stock issued and outstanding.
Series C Preferred Stock
The Board of Directors of the Company have designated 300,000 shares as Series C Preferred Stock. The Designation of the Series C Preferred Stock, as amended, includes a liquidation preference of $10.00 per share. The Series C Preferred Stock has no voting rights and no conversion rights. As of March 31, 2017 and December 31, 2016 there are 300,000 shares of Series C Preferred Stock issued and outstanding.
When you think "there can't be that many people falling for this", remember the Bernie Madoff story and recall that over $50 BILLION of smart money fell for a great story.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM